The vision of precision medicine is to enable doctors, researchers and others to more accurately predict and prescribe appropriate treatments based on individuals genetic profile and other factors. Our virtual MedCity INVEST Precision Medicine conference, December 9-11, will highlight some aspects of this exciting area from the biopharma companies developing cell and gene therapies to diagnostics and the data sharing initiatives to support precision and personalized medicine.
Here’s a preview of some of the sessions, but you can see the agenda here.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
What Does the Diagnostics Landscape Look Like?
Diagnostics is joined at the hip with precision medicine. The rapidly evolving field has led to the ability to quickly, reliably and affordably sequence an individual’s entire genome and the development of screening tests and companion diagnostics for a wide range of diseases. Hear perspectives on the opportunities and challenges in this sector.
Brad Bostic, Founder and CEO, hc1
Peter Hulick, M.D., Medical Director, NorthShore University Health System
Nicole Lambert, President of Myriad Genetic Laboratories, Myriad Genetics
Moderator: John Younger, M.D., Founding Partner, Argo Pond Consulting
Investment Trends in Precision Medicine
Join us for a discussion on investments year-to-date for health-tech and life science companies and the impact of M&A deals from 2019. How have investment strategies and priorities changed? How do they work with startups/growth stage companies? How are strategic investors changing the investment landscape? What have they learned from investment missteps and successes?
Julie Grant, General Partner, Canaan
Jeffrey Low, M.D., Principal, Novo Growth
Christopher McFadden, Managing Director, KKR Credit
What It Takes To Build A Successful, Regional BioInnovation Hub
Philadelphia is one of many cities seeking to support the continued growth of cell and gene therapy and connected health industries. What do cities need to do to address education, training and other needs to support these sectors? This session will be held as part of Venture Cafe Philadelphia.
(sponsored by IBX)
Lisa Dalton, Chief People Officer, Spark Therapeutics
Audrey Greenberg, Executive Managing Director, The Discovery Labs
Tiffany Wilson, President & CEO, University City Science Center
Moderator: Michelle Histand, Director of Innovation, Independence Blue Cross
Register now and be part of the conversation at INVEST Precision Medicine.